Current Report Filing (8-k)
18 Maio 2016 - 6:15PM
Edgar (US Regulatory)
UNITED STATES SECURITIES AND EXCHANGE
COMMISSION
WASHINGTON, D.C. 20549
_________________________
FORM 8-K
CURRENT REPORT PURSUANT TO SECTION 13
OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported):
May 18, 2016
CHAMPIONS ONCOLOGY, INC.
(Exact name of registrant as specified in
its charter)
Delaware
|
001-11504
|
52-1401755
|
(State or Other Jurisdiction
|
(Commission File Number)
|
(IRS Employer
|
of Incorporation)
|
|
Identification No.)
|
1 University Plaza, Suite 307, Hackensack,
New Jersey 07601
(Address of Principal Executive Offices)
Registrant’s telephone number, including
area code:
(410) 369-0365
Not Applicable
(Former Name or Former Address if Changed
Since Last Report)
Check the appropriate box below if the
Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|
¨
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
¨
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
¨
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
¨
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Item 7.01. Regulation FD Disclosure.
Commencing shortly after the filing of this
Current Report on Form 8-K, representatives of Champions Oncology, Inc. (the “Company”) intend to hold presentations
for investors, analysts and others. A copy of the written materials that the Company intends to use in connection with these presentations
(the “Slides”) is attached as Exhibit 99.1 to this Current Report on Form 8-K.
By filing this Current Report on Form 8-K
and furnishing the information contained herein, the Company makes no admission as to the materiality of any information in this
report that is required to be disclosed solely by reason of Regulation FD.
The information contained in the Slides
is summary information that is intended to be considered in the context of the Company's Securities and Exchange Commission (“SEC”)
filings and other public announcements that the Company may make, by press release or otherwise, from time to time. The Company
undertakes no duty or obligation to publicly update or revise the information contained in this report, although it may do so from
time to time as its management believes is warranted. Any such updating may be made through the filing of other reports or documents
with the SEC, through press releases or through other public disclosure.
The information presented herein and in
Exhibit 99.1 shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as
amended (the “Exchange Act”), or otherwise subject to the liabilities of that section.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits
The following exhibit filed herewith:
Exhibit No.
99.1 Investor Relations Slideshow in use beginning May 18,
2016 (furnished only).
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned
thereunto duly authorized.
|
CHAMPIONS ONCOLOGY, INC.
|
|
|
|
|
Date: May 18, 2016
|
By:
/s/ Joel Ackerman
|
|
Joel Ackerman
|
|
Chief Executive Officer
|
Champions Oncology (NASDAQ:CSBR)
Gráfico Histórico do Ativo
De Jun 2024 até Jul 2024
Champions Oncology (NASDAQ:CSBR)
Gráfico Histórico do Ativo
De Jul 2023 até Jul 2024